Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00009-9/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ascogu25&_hsenc=p2ANqtz-9bPLJ27tVEdKQhkncwYHpwYj_PKroX842t9eX7_xzt69Yix7WZGM_kQjppDapQEm0GMiz2UXs6wpeIutVCec8caDPqUQ&_hsmi=348374471&utm_content=347180122&utm_source=hs_email